Mr. Donald Fresne, Chairman
and CEO of Egenix, Inc., announced today that the company has recently
obtained from Harvard University a field-exclusive license under patent
rights that cover certain technologies related to cancer therapy and
prognostic testing. The licensed technologies, which were developed jointly
by scientists in the Laboratory for Translational Research and the
Department of Biological Chemistry and Molecular Pharmacology, each of
Harvard Medical School, comprise small molecule inhibitors of translation
initiation, a new paradigm in target- specific, non-cytotoxic anti-cancer
therapy, and the use of translation initiation-specific biomarkers to
assess tumor sensitivity to anti-cancer therapy with this novel class of
anti-cancer drugs. Specifically, the inhibitors of translation initiation
licensed by Egenix from Harvard Medical School target the eIF4F and ternary
complexes, the two critical regulators of messenger RNA translation into
protein.
The company's management believes that small molecules for the
inhibition of translation initiation are at the forefront of modern cancer
therapeutics currently under development and that this cutting-edge
platform has the potential to yield significant breakthroughs in the
biomedical field for the treatment of cancer.
Egenix, Inc.
Based in Millbrook, New York, Egenix, Inc. is a privately held
biotechnology company responding to the demand for more effective cancer
therapies.
Terms and conditions of the license agreement are not disclosed.
SOURCE Egenix, Inc.
Digg
Reddit
Slashdot